Does mutated K-RAS oncogene attenuate the effect of Sulindac in colon cancer chemoprevention?

The non-steroidal anti-inflammatory drug (NSAID) Sulindac has been successfully used alone or in combination with other agents to suppress colon tumorigenesis in patients with genetic predisposition, and also showed its efficacy in prevention of sporadic colon adenomas. At the same time, some experi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Prev Res (Phila)
Autors principals: Rice, Photini FS., Ehrichs, Kevin G., Jones, Mykella S., Chen, Hwudarw, Hsu, Chiu-Hsieh, Abril, Edward R., Nagle, Raymond B., Besselsen, David G., Barton, Jennifer K., Ignatenko, Natalia A.
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7733710/
https://ncbi.nlm.nih.gov/pubmed/29118162
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1940-6207.CAPR-17-0230
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars